Latest updates
- In the press OBN Awards 2025
- In the press Exonate plans ‘CLEAR-DE’ Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease
- In the press Exonate appoints Dr Rafiq Hasan as Non-Executive Director
- In the press Exonate Shortlisted for Biotech Company of the Year by The Cambridge Independent Science and Technology Awards.
- In the press Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
- In the press Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
- In the press Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema
- In the press Exonate announces the initiation of Phase Ib/II clinical trial for Diabetic Macular Oedema, as part of its collaboration with Janssen
- In the press A day in the life of a Senior Scientist
- In the press Exonate Announces Collaboration with Janssen to develop a new eye drop for the treatment of retinal vascular diseases including wet age-related macular degeneration (AMD) and diabetic macular oedema (DMO)
- In the press Watch Exonate’s Dr. Catherine Beech OBE accept Top 21 #OnetoWatch award from Cofinitve
- In the press Exonate closes successful £1.5 million fundraising